Nayak et al. reported that IKM5 (2-(1-(1H-indol-3-yl)octyl)-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one), a novel indolylkojyl methane analogue, inhibits EMT and invasion in breast cancer cells by binding to GRP78 and decreasing its expression along with the downregulation of EMT markers, such as vimentin, Twist1, and MMP2 [221]. This evidence concerns the gene HSPA5 and breast cancer.